Analyst consensus rating
Eikon Therapeutics Analyst Rating: Buy
Direct answer
Eikon Therapeutics's consensus rating is Buy.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $24.33.
Forecast evidence checked November 14, 2026.
Get free Eikon Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $5.98
- Average price target
- $24.33
- High price target
- $32.00
- Low price target
- $4.00
- Low target gap
- -33.1%
- Target upside
- +306.9%
- High target gap
- +435.1%
- Target range width
- 468.2%
- Consensus rating
- Buy
- Analysts
- 6
- Evidence date
- November 14, 2026
- Valid through
- November 21, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Eikon Therapeutics?
Eikon Therapeutics has a verified Buy consensus. The same dataset has an average price target of $24.33.
How far are Eikon Therapeutics's low and high targets from the recorded price?
The low target implies -33.1%, while the high target implies +435.1%.
How many analysts are included in Eikon Therapeutics's consensus?
The verified consensus includes 6 analysts.
How is Eikon Therapeutics's target upside or downside calculated?
The average target of $24.33 is divided by the recorded price of $5.98, then one is subtracted to produce +306.9%. This does not guarantee a future return.
When was Eikon Therapeutics's analyst forecast verified?
The data was verified on 2026-11-14. The dataset is valid through 2026-11-21.